Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.17
SPNC's Cash to Debt is ranked lower than
88% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. SPNC: 0.17 )
Ranked among companies with meaningful Cash to Debt only.
SPNC' s Cash to Debt Range Over the Past 10 Years
Min: 0.17  Med: 10000.00 Max: No Debt
Current: 0.17
Equity to Asset 0.29
SPNC's Equity to Asset is ranked lower than
88% of the 295 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. SPNC: 0.29 )
Ranked among companies with meaningful Equity to Asset only.
SPNC' s Equity to Asset Range Over the Past 10 Years
Min: 0.29  Med: 0.73 Max: 0.89
Current: 0.29
0.29
0.89
F-Score: 2
Z-Score: 0.63
M-Score: -2.52
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -23.26
SPNC's Operating margin (%) is ranked lower than
67% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 1.89 vs. SPNC: -23.26 )
Ranked among companies with meaningful Operating margin (%) only.
SPNC' s Operating margin (%) Range Over the Past 10 Years
Min: -18.03  Med: -2.49 Max: 4.35
Current: -23.26
-18.03
4.35
Net-margin (%) -26.67
SPNC's Net-margin (%) is ranked lower than
68% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 0.95 vs. SPNC: -26.67 )
Ranked among companies with meaningful Net-margin (%) only.
SPNC' s Net-margin (%) Range Over the Past 10 Years
Min: -19.96  Med: -1.26 Max: 8.72
Current: -26.67
-19.96
8.72
ROE (%) -44.09
SPNC's ROE (%) is ranked lower than
78% of the 286 Companies
in the Global Medical Devices industry.

( Industry Median: 2.05 vs. SPNC: -44.09 )
Ranked among companies with meaningful ROE (%) only.
SPNC' s ROE (%) Range Over the Past 10 Years
Min: -23.23  Med: -1.51 Max: 8.5
Current: -44.09
-23.23
8.5
ROA (%) -14.35
SPNC's ROA (%) is ranked lower than
64% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: -0.07 vs. SPNC: -14.35 )
Ranked among companies with meaningful ROA (%) only.
SPNC' s ROA (%) Range Over the Past 10 Years
Min: -13.44  Med: -1.23 Max: 7.25
Current: -14.35
-13.44
7.25
ROC (Joel Greenblatt) (%) -78.25
SPNC's ROC (Joel Greenblatt) (%) is ranked lower than
67% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 3.57 vs. SPNC: -78.25 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SPNC' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -64.94  Med: -7.91 Max: 34.27
Current: -78.25
-64.94
34.27
Revenue Growth (3Y)(%) 10.00
SPNC's Revenue Growth (3Y)(%) is ranked higher than
73% of the 209 Companies
in the Global Medical Devices industry.

( Industry Median: 3.60 vs. SPNC: 10.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SPNC' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -3.7  Med: 7.15 Max: 29.4
Current: 10
-3.7
29.4
» SPNC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

SPNC Guru Trades in Q4 2014

Steven Cohen 70,900 sh (New)
Ron Baron 270,280 sh (-12.74%)
» More
Q1 2015

SPNC Guru Trades in Q1 2015

Steven Cohen 559,000 sh (+688.43%)
Ron Baron 862,579 sh (+219.14%)
» More
Q2 2015

SPNC Guru Trades in Q2 2015

Ron Baron 2,340,509 sh (+171.34%)
Steven Cohen 187,300 sh (-66.49%)
» More
Q3 2015

SPNC Guru Trades in Q3 2015

Steven Cohen 753,700 sh (+302.40%)
Ron Baron 2,120,500 sh (-9.40%)
» More
» Details

Insider Trades

Latest Guru Trades with SPNC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on The Spectranetics Corp

Baron Funds Comments on The Spectranetics Corp. - Aug 19, 2015

The Spectranetics Corporation (NASDAQ:SPNC) is a medical device company that specializes in equipment that clears plaque from cardiac and peripheral (arm and leg) arteries. Shares fell after the company reported that it had missed revenues in the first quarter and lowered full year guidance. We believe the market misunderstood certain dynamics and bought more near the bottom. (Randy Gwirtzman)





From Baron Funds’ second quarter 2015 commentary.



Check out Ron Baron latest stock trades

Baron Funds Comments on Spectranetics Corporation - Feb 26, 2014

The Spectranetics Corporation (NASDAQ:SPNC) is a manufacturer of medical devices that assist in the treatment of peripheral arterial disease and also with the removal of coronary leads used for implanted devices such as pacemakers and defibrillators. Shares were up 46% in the quarter. Most of the company's devices use disposable products that lead to a highly recurring revenue stream. The company is on the verge of opening up large new markets with the expected 2014 approval of a new laser based device that can open up arteries that have previously been stented. If approved, it will be the only device on the market that has this capability.



From Ron Baron (Trades, Portfolio)'s Baron Funds fourth quarter 2013 letter to shareholders.

Check out Ron Baron latest stock trades

Top Ranked Articles about The Spectranetics Corp

Steven Cohen's Point72 Raises Stake in Spectranetics Purchase increases position by more than 1,000%
Steven Cohen (Trades, Portfolio)’s hedge fund Point72 Asset Management increased an existing stake in The Spectranetics Corp. (NASDAQ:SPNC), a Colorado Springs, Colo.-based manufacturer of single-use medical devices for minimally invasive cardiovascular procedures, by more than 1,000% on Oct. 8. Read more...
Baron Funds Comments on The Spectranetics Corp.
The Spectranetics Corporation (NASDAQ:SPNC) is a medical device company that specializes in equipment that clears plaque from cardiac and peripheral (arm and leg) arteries. Shares fell after the company reported that it had missed revenues in the first quarter and lowered full year guidance. We believe the market misunderstood certain dynamics and bought more near the bottom. (Randy Gwirtzman) Read more...

Ratios

vs
industry
vs
history
Forward P/E 357.14
SPNC's Forward P/E is ranked lower than
98% of the 177 Companies
in the Global Medical Devices industry.

( Industry Median: 18.66 vs. SPNC: 357.14 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 3.99
SPNC's P/B is ranked lower than
75% of the 385 Companies
in the Global Medical Devices industry.

( Industry Median: 2.63 vs. SPNC: 3.99 )
Ranked among companies with meaningful P/B only.
SPNC' s P/B Range Over the Past 10 Years
Min: 0.78  Med: 4.37 Max: 13.1
Current: 3.99
0.78
13.1
P/S 2.05
SPNC's P/S is ranked higher than
54% of the 382 Companies
in the Global Medical Devices industry.

( Industry Median: 2.24 vs. SPNC: 2.05 )
Ranked among companies with meaningful P/S only.
SPNC' s P/S Range Over the Past 10 Years
Min: 0.69  Med: 3.89 Max: 8.47
Current: 2.05
0.69
8.47
Current Ratio 1.65
SPNC's Current Ratio is ranked lower than
73% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 2.66 vs. SPNC: 1.65 )
Ranked among companies with meaningful Current Ratio only.
SPNC' s Current Ratio Range Over the Past 10 Years
Min: 1.4  Med: 2.76 Max: 8.52
Current: 1.65
1.4
8.52
Quick Ratio 1.26
SPNC's Quick Ratio is ranked lower than
70% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. SPNC: 1.26 )
Ranked among companies with meaningful Quick Ratio only.
SPNC' s Quick Ratio Range Over the Past 10 Years
Min: 1.2  Med: 2.37 Max: 7.99
Current: 1.26
1.2
7.99
Days Inventory 154.62
SPNC's Days Inventory is ranked lower than
56% of the 281 Companies
in the Global Medical Devices industry.

( Industry Median: 142.23 vs. SPNC: 154.62 )
Ranked among companies with meaningful Days Inventory only.
SPNC' s Days Inventory Range Over the Past 10 Years
Min: 82.36  Med: 86.54 Max: 119.22
Current: 154.62
82.36
119.22
Days Sales Outstanding 60.01
SPNC's Days Sales Outstanding is ranked higher than
64% of the 266 Companies
in the Global Medical Devices industry.

( Industry Median: 72.25 vs. SPNC: 60.01 )
Ranked among companies with meaningful Days Sales Outstanding only.
SPNC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 48.49  Med: 58.06 Max: 73.19
Current: 60.01
48.49
73.19
Days Payable 54.39
SPNC's Days Payable is ranked lower than
54% of the 256 Companies
in the Global Medical Devices industry.

( Industry Median: 59.85 vs. SPNC: 54.39 )
Ranked among companies with meaningful Days Payable only.
SPNC' s Days Payable Range Over the Past 10 Years
Min: 14.31  Med: 21.02 Max: 241.52
Current: 54.39
14.31
241.52

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.54
SPNC's Price/Median PS Value is ranked higher than
88% of the 374 Companies
in the Global Medical Devices industry.

( Industry Median: 0.99 vs. SPNC: 0.54 )
Ranked among companies with meaningful Price/Median PS Value only.
SPNC' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.2  Med: 0.91 Max: 1.97
Current: 0.54
0.2
1.97
Price/Graham Number 1.13
SPNC's Price/Graham Number is ranked higher than
74% of the 248 Companies
in the Global Medical Devices industry.

( Industry Median: 2.73 vs. SPNC: 1.13 )
Ranked among companies with meaningful Price/Graham Number only.
SPNC' s Price/Graham Number Range Over the Past 10 Years
Min: 1.1  Med: 5.33 Max: 17.4
Current: 1.13
1.1
17.4
Earnings Yield (Greenblatt) (%) -8.03
SPNC's Earnings Yield (Greenblatt) (%) is ranked lower than
70% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 0.70 vs. SPNC: -8.03 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SPNC' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -7.89  Med: 0.70 Max: 31.1
Current: -8.03
-7.89
31.1

More Statistics

Revenue(Mil) $244
EPS $ -1.54
Beta1.51
Short Percentage of Float20.81%
52-Week Range $10.65 - 37.04
Shares Outstanding(Mil)42.64

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 245 262 283
EPS($) -1.00 -0.80 -0.42
EPS without NRI($) -1.00 -0.80 -0.42

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:SC7.Germany,
The Spectranetics Corp is incorporated under the laws of Delaware and formed in 1984. The Company develops, manufactures, markets and distributes single-use medical devices used in minimally invasive procedures within the cardiovascular system. The Company has two operating segments that are identified on a geographic basis: U.S. Medical and International Medical. U.S. Medical and International Medical offer the same products and services but operate in different geographic regions, have different distribution networks and different regulatory environments. Its products are used to treat arterial blockages in the heart and legs and to remove pacemaker and defibrillator cardiac leads. Approximately 68% of its disposable product revenue is from products used in connection with its proprietary excimer laser system, the CVX-300. Its single-use laser catheters contain up to 250 small diameters, flexible optical fibers that can access difficult to reach peripheral and coronary anatomy and produce evenly distributed laser energy at the tip of the catheter for more uniform ablation. Its disposable products are develops in two categories: Vascular Intervention (VI) and Lead Management (LM). Vascular Intervention products include; support catheters to facilitate crossing of peripheral and coronary arterial blockages, and retrograde access and guidewire retrieval devices used in the treatment of peripheral arterial blockages, including chronic total occlusions, drug delivery catheters for vascular delivery of drugs and diagnostic agents. Lead Management products include: excimer laser sheaths; non-laser sheaths; and cardiac lead management accessories for the removal of pacemaker and defibrillator cardiac leads. Its competitors are manufacturers of products used in competing therapies within the peripheral and coronary atherectomy markets, such as: atherectomy and thrombectomy, using mechanical methods to remove arterial blockages, balloon angioplasty and stents, specialty balloon angioplasty, bypass surgery and amputation. The Company's products are medical devices subject to extensive regulation by the FDA under the Federal Food, Drug, and Cosmetic Act, or FDCA. FDA regulations govern.
» More Articles for SPNC

Headlines

Articles On GuruFocus.com
Steven Cohen's Point72 Raises Stake in Spectranetics Oct 22 2015 
Baron Funds Comments on The Spectranetics Corp. Aug 19 2015 
Baron Funds Comments on Spectranetics Corporation Feb 26 2014 
Spectranetics Corp. Reports Operating Results (10-Q) Nov 08 2010 
Spectranetics Corp. Reports Operating Results (10-Q) Nov 06 2009 
Spectranetics Corp. Reports Operating Results (10-Q) Aug 10 2009 
Spectranetics Corp. Reports Operating Results (10-Q) May 11 2009 
Weekly CEO Buys Highlight: Spectranetics Corp., Noven Pharmaceuticals Inc., Dolan Media Company, Mod Sep 09 2008 

More From Other Websites
QT Vascular Announces Another Positive Outcome in Litigation with Spectranetics/Angioscore Feb 10 2016
Spectranetics to Hold 2015 Fourth Quarter Financial Results Conference Call on February 25, 2016 Feb 09 2016
SPECTRANETICS CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Feb 08 2016
Spectranetics Receives FDA 510(k) Clearance for Bridge™ Occlusion Balloon for Lead Extraction... Feb 08 2016
Why Spectranetics Stock Will Continue to Fall Feb 02 2016
Why These 5 Stocks Are Immersed in a Sea of Red Today Jan 22 2016
The Spectranetics Corp. – Value Analysis (NASDAQ:SPNC) : January 20, 2016 Jan 20 2016
The Spectranetics Corp. breached its 50 day moving average in a Bearish Manner : January 20, 2016 Jan 20 2016
Spectranetics Shareholders and Former Employees Are Encouraged to Contact Court Appointed Lead... Jan 11 2016
SPECTRANETICS CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Jan 11 2016
Robbins Arroyo LLP is Investigating the Officers and Directors of The Spectranetics Corporation... Dec 30 2015
A Refreshing Outlook - Research Reports on Cobalt International Energy, Merrimack Pharmaceuticals,... Dec 29 2015
Spectranetics to Present at the J.P. Morgan 34th Annual Healthcare Conference Dec 28 2015
Spectranetics to Present at the J.P. Morgan 34th Annual Healthcare Conference Dec 28 2015
Buy These 5 Stocks Now to Catch the Breakouts Dec 11 2015
Spectranetics Announces FDA Submission of Bridge(TM) Occlusion Balloon for Lead Extraction... Dec 08 2015
Spectranetics Announces FDA Submission of Bridge(TM) Occlusion Balloon for Lead Extraction... Dec 08 2015
SPECTRANETICS CORP Financials Dec 08 2015
Spectranetics Announces Debt Financing Dec 07 2015
SPECTRANETICS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a... Dec 07 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK